Investigation of Two Potential Predictors of Thrombosis Risk in Polycythemia Vera: Hematocrit-to-Hemoglobin Ratio and HALP Score
- PMID: 40452364
- PMCID: PMC12134513
- DOI: 10.1177/10760296251347630
Investigation of Two Potential Predictors of Thrombosis Risk in Polycythemia Vera: Hematocrit-to-Hemoglobin Ratio and HALP Score
Abstract
Objective: This study aimed to assess the utility of the hematocrit-to-hemoglobin ratio (HHR) and the HALP score in detecting thrombosis history in patients with polycythemia vera (PV). Methods: This retrospective study examined patients diagnosed with PV between January 2013 and December 2022. Demographics, clinical history, PV- and thrombosis-related data, laboratory findings, follow-up duration, and mortality status were retrieved from hospital records. HHR and HALP scores were calculated for all patients. Patients were grouped based on their thrombosis history. Results: A total of 124 PV patients were included, with a mean age of 57.65 ± 12.17 years, and 86 (69.35%) were males. Thrombosis was present in 59 patients (47.58%), with 32.20% occurring before diagnosis, 23.73% at diagnosis, and 44.07% after diagnosis. Patients with and without thrombosis history were similar in age and sex. Those with a history of thrombosis had significantly higher anticoagulant use and HHR values, while other variables, including HALP score, showed no differences. An HHR cut-off value of >3.05 predicted thrombosis history with 54.24% sensitivity and 72.31% specificity. Conclusion: HHR could help distinguish PV patients with thrombosis history, though its sensitivity is low. HALP score was not associated with thrombosis risk.
Keywords: hematocrit; hemoglobins; polycythemia vera; risk factors; thrombosis.
Conflict of interest statement
Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
Similar articles
-
Hematocrit to hemoglobin ratio as a prognostic marker in polycythemia vera.Wien Klin Wochenschr. 2022 Feb;134(3-4):110-117. doi: 10.1007/s00508-021-01967-z. Epub 2021 Nov 4. Wien Klin Wochenschr. 2022. PMID: 34738212
-
Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data.Ann Hematol. 2019 Nov;98(11):2533-2539. doi: 10.1007/s00277-019-03793-w. Epub 2019 Sep 24. Ann Hematol. 2019. PMID: 31552445 Free PMC article.
-
Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.Int J Hematol. 2017 Jan;105(1):70-78. doi: 10.1007/s12185-016-2105-0. Epub 2016 Oct 3. Int J Hematol. 2017. PMID: 27699575
-
Laboratory investigations and prediction of thrombotic risk in polycythemia vera.Nouv Rev Fr Hematol (1978). 1994 Apr;36(2):183-5. Nouv Rev Fr Hematol (1978). 1994. PMID: 8036139 Review.
-
Diagnosis and Treatment of Polycythemia Vera: A Review.JAMA. 2025 Jan 14;333(2):153-160. doi: 10.1001/jama.2024.20377. JAMA. 2025. PMID: 39556352 Review.
References
-
- Yalçınkaya R, Zenciroğlu A. Evaluation of neonatal polycythemia in terms of gestational age, hematocrit, and platelet levels. Turk J Pediatr Dis. 2022;16(6):495-500. doi:10.12956/tchd.1016684 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical